Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Stock analysts at SunTrust Banks raised their FY2017 earnings per share (EPS) estimates for Alexion Pharmaceuticals in a research report issued to clients and investors on Tuesday. SunTrust Banks analyst Y. Suneja now expects that the biopharmaceutical company will post earnings per share of $4.71 for the year, up from their previous forecast of $4.70. SunTrust Banks currently has a “Buy” rating and a $180.00 target price on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Deutsche Bank AG restated a “buy” rating and set a $158.00 price target (up from $153.00) on shares of Alexion Pharmaceuticals in a report on Wednesday. Leerink Swann restated an “outperform” rating and set a $182.00 price target (up from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday. They noted that the move was a valuation call. BMO Capital Markets reaffirmed an “outperform” rating and set a $173.00 price objective (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday. J P Morgan Chase & Co raised shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $163.00 to $175.00 in a research report on Tuesday, September 5th. Finally, BidaskClub raised shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, August 20th. Five analysts have rated the stock with a hold rating, twenty have issued a buy rating and three have given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $157.74.

WARNING: This article was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/09/14/fy2017-eps-estimates-for-alexion-pharmaceuticals-inc-alxn-lifted-by-suntrust-banks.html.

Shares of Alexion Pharmaceuticals (ALXN) opened at 146.46 on Thursday. Alexion Pharmaceuticals has a one year low of $96.18 and a one year high of $149.34. The company has a market capitalization of $32.69 billion, a price-to-earnings ratio of 63.51 and a beta of 1.40. The company has a 50-day moving average price of $137.59 and a 200 day moving average price of $124.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business had revenue of $912.00 million for the quarter, compared to analyst estimates of $846.15 million. During the same period in the previous year, the company earned $1.13 earnings per share. The company’s revenue for the quarter was up 21.1% compared to the same quarter last year.

In other news, EVP Julie O’neill sold 11,160 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the sale, the executive vice president now owns 26,704 shares of the company’s stock, valued at $3,738,560. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Ann M. Veneman sold 700 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the sale, the director now directly owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 17,070 shares of company stock valued at $2,416,869. Company insiders own 4.35% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of Alexion Pharmaceuticals by 7.0% during the second quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock valued at $2,424,428,000 after purchasing an additional 1,298,185 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Alexion Pharmaceuticals by 2.2% during the second quarter. Vanguard Group Inc. now owns 14,785,831 shares of the biopharmaceutical company’s stock valued at $1,798,992,000 after purchasing an additional 318,375 shares during the last quarter. State Street Corp grew its stake in shares of Alexion Pharmaceuticals by 5.0% during the second quarter. State Street Corp now owns 11,860,647 shares of the biopharmaceutical company’s stock valued at $1,443,099,000 after purchasing an additional 561,962 shares during the last quarter. Ameriprise Financial Inc. grew its stake in shares of Alexion Pharmaceuticals by 0.4% during the second quarter. Ameriprise Financial Inc. now owns 6,175,296 shares of the biopharmaceutical company’s stock valued at $751,363,000 after purchasing an additional 25,724 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Alexion Pharmaceuticals by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 3,349,821 shares of the biopharmaceutical company’s stock valued at $407,573,000 after purchasing an additional 64,800 shares during the last quarter. 94.26% of the stock is currently owned by institutional investors and hedge funds.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.